HomeInsightsStock Comparison

Astrazeneca Pharma India Ltd vs Influx Healthtech Ltd Stock Comparison

Astrazeneca Pharma India Ltd vs Influx Healthtech Ltd Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

  • The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8231 as of 04 May 09:44 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Influx Healthtech Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Influx Healthtech Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Influx Healthtech Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Influx Healthtech Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Influx Healthtech Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Influx Healthtech Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Influx Healthtech Ltd

  • Influx Healthtech Limited was originally incorporated on September 28, 2020 as a Private Limited Company as 'Influx Healthtech Private Limited' with the Registrar of Companies, Central Registration Centre.
  • Company converted from a Private Limited to Public Limited and the name of Company was changed to Influx Healthtech Limited' and a Fresh Certificate of Incorporation upon the conversion was issued on May 23, 2022 by the Registrar of Companies, Mumbai. Influx Healthtech Limited is a a Mumbai-based healthcare product-focused company that has carved a niche in manufacturing Soft Gelatin, Tablets, Capsules, Liquid Orals, Oral Powders, Liquid fill capsules, Effervescent tablets, Nutra Pallets, Protein Bars, Cookies, Jellies/ Gummies, External preparations like Creams, Gels, Ointments, External Oils, Soaps, etc.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Influx Healthtech Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Influx Healthtech Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of Influx Healthtech Ltd is 622 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Influx Healthtech Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Influx Healthtech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Influx Healthtech Ltd?

As of May 4, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, Influx Healthtech Ltd stock price is INR ₹268.9.

How do dividend payouts of Astrazeneca Pharma India Ltd and Influx Healthtech Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Influx Healthtech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions